More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants

[1]  A. Tam,et al.  SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster , 2023, The Lancet Infectious Diseases.

[2]  Stephen J. Thomas,et al.  Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years , 2023, The New England journal of medicine.

[3]  M. Hogardt,et al.  Molecular surveillance of multidrug-resistant Gram-negative bacteria in Ukrainian patients, Germany, March to June 2022 , 2023, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  Mihir Melwani.  How war is spreading drug resistant superbugs across Ukraine and beyond , 2022, BMJ.

[5]  S. Ciesek,et al.  Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice , 2022, Science immunology.

[6]  Larissa B. Thackray,et al.  Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice , 2022, Nature Medicine.

[7]  Michael John Smith,et al.  SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses , 2022, medRxiv.

[8]  B. T. Jones,et al.  Phenotypic and Genotypic Characterization of Antibiotic Resistance in Military Hospital-Associated Bacteria from War Injuries in the Eastern Ukraine Conflict between 2014 and 2020. , 2021, The Journal of hospital infection.

[9]  H. Frickmann,et al.  Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Isolated from War-Injured Patients from the Eastern Ukraine , 2020, Antibiotics.

[10]  D. Hospenthal,et al.  Recovery of multidrug-resistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. , 2009, Military medicine.